Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Nutr Sci Vitaminol (Tokyo) ; 68(5): 409-419, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36310075

RESUMO

Nonalcoholic steatohepatitis (NASH) is associated with several cardiovascular risk factors, including atherogenic dyslipidemia. Recently, fasting prior to lipid profile evaluation has been thought to be unnecessary for most individuals. We investigated the impact of fasting for up to 9 h on the serum and hepatic lipid profiles in Sprague-Dawley (SD) rats of dietary-induced NASH model in comparison to SD rats fed a normal diet. In both groups, fasting affected the serum and hepatic triglyceride (TG), serum free fatty acid (FFA) and leptin levels, histopathologically assessed hepatocyte ballooning, and hepatic mRNA expression levels of several genes related to lipid metabolism. In contrast, the serum adiponectin and aminotransferase levels, serum and hepatic total cholesterol contents, and liver histopathological findings of hepatic steatosis, lobular inflammation and fibrosis were not influenced by fasting. A significant fasting time-dependent reduction was seen in the serum TG level only in the normal SD rats group. Regarding the hepatic TG level, a significant fasting time-dependent increase was seen only in the NASH model rat group. A significant fasting time-dependent reduction was also seen in the serum FFA level only in the NASH model rat group. Our present results indicate that excessive fasting can be avoided before blood or hepatic tissue sampling for the evaluation of several parameters in non-NASH and/or NASH model rats. Further investigations are needed in humans to determine whether excessive fasting before blood or hepatic tissue sampling can be avoided in both healthy individuals and NASH patients.


Assuntos
Hepatopatia Gordurosa não Alcoólica , Animais , Ratos , Modelos Animais de Doenças , Jejum , Fígado/metabolismo , Hepatopatia Gordurosa não Alcoólica/metabolismo , Ratos Sprague-Dawley , Triglicerídeos , Metabolismo dos Lipídeos
2.
Endocr J ; 69(12): 1457-1465, 2022 Dec 28.
Artigo em Inglês | MEDLINE | ID: mdl-35896344

RESUMO

The postoperative increase in glucagon-like peptide-1 (GLP-1) is the main factor to improve glucose metabolism following sleeve gastrectomy (SG) in obese patients with type 2 diabetes. We investigated whether the ß-cell responsiveness to an injection of exogenous GLP-1 in the preoperative period could determine the postoperative glucose tolerance in 18 patients underwent SG. In the preoperative period, a regular oral glucose tolerance test (OGTT) and an exenatide-challenge during OGTT (Ex-OGTT) were performed to evaluate the ß-cell function and its responsiveness to GLP-1. The postoperative glucose tolerance was evaluated by another regular OGTT performed at 3 months after SG. The significant decrease in glucose levels with enhanced secretions of insulin and GLP-1 was observed in OGTT at 3 months after SG. The area under the curve of glucose from 0 to 120 minutes (AUC glucose0-120 min) and the insulinogenic index (I.I.) in OGTT at 3 months post-SG were significantly improved compared to those in preoperative period, but comparable with those in Ex-OGTT. AUC glucose0-120 min and I.I. in OGTT at 3 months post-SG were significantly correlated with not only those in Ex-OGTT, but also those in the preoperative regular OGTT. Conversely, the correlations calculated by the Spearman's ρ were stronger in the latter than the former. This exenatide-challenge protocol might be useful to estimate glucose tolerance and insulin secretion after SG, however, it may be insufficient to improve predictability of a patient who is likely to achieve a significant benefit on glucose metabolism from receiving SG.


Assuntos
Diabetes Mellitus Tipo 2 , Peptídeo 1 Semelhante ao Glucagon , Humanos , Teste de Tolerância a Glucose , Secreção de Insulina , Exenatida , Projetos Piloto , Diabetes Mellitus Tipo 2/metabolismo , Obesidade/complicações , Obesidade/cirurgia , Insulina/metabolismo , Glucose , Gastrectomia/métodos , Glicemia/metabolismo
3.
Diabetes Res Clin Pract ; 135: 178-184, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29162514

RESUMO

AIMS: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) cause substantially less weight loss than would be expected based on their caloric deficits, probably due to enhanced appetite regulation known as "compensatory hyperphagia," which occurs to offset the negative energy balance caused by increased glycosuria. We examined whether any specific nutrients contributed to the compensatory hyperphagia in diabetic patients taking SGLT2i. METHODS: Sixteen patients with type 2 diabetes were newly administered dapagliflozin 5 mg daily as the experimental SGLT2i group. Sixteen age-, sex- and BMI-matched type 2 diabetes patients not receiving dapagliflozin served as controls. A brief-type self-administered diet history questionnaire (BDHQ) was undertaken just before and 3 months after study initiation to evaluate changes of energy and nutrient intakes in each group. RESULTS: At 3 months, daily intakes of total calories and the proportions of the three major nutrients were not significantly increased in either group. However, daily sucrose intake was significantly increased after treatment versus the baseline value in the SGLT2i group (p = .003), but not in controls. The calculated intakes of all other nutrients were not significantly changed in either group. CONCLUSIONS: Dapagliflozin treatment specifically increased sucrose intake, which might be an ideal target for nutritional approaches to attenuate compensatory hyperphagia.


Assuntos
Compostos Benzidrílicos/efeitos adversos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Glucosídeos/efeitos adversos , Hiperfagia/etiologia , Proteínas de Transporte de Sódio-Glucose/efeitos adversos , Açúcares/metabolismo , Adolescente , Adulto , Idoso , Compostos Benzidrílicos/farmacologia , Diabetes Mellitus Tipo 2/patologia , Ingestão de Energia , Feminino , Glucosídeos/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas de Transporte de Sódio-Glucose/farmacologia , Inquéritos e Questionários , Adulto Jovem
4.
J Nutr Sci Vitaminol (Tokyo) ; 56(6): 387-95, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21422708

RESUMO

To investigate the available energy of orally administered [(14)C]mannitol via intestinal microbes, [(14)C]mannitol (222 kBq, 105 mg) or [(14)C]glucose (222 kBq, 105 mg) was administered to conventional rats and antibiotics-treated rats whose intestinal microbes were depleted by drinking water containing antibiotics, respectively. The exhausted CO(2), feces and urine were then separately collected at 2, 4, 6, 8, 10, 12 and 24 h after administration of the test solution. In the conventional rats, 45% of administered radioactivity was recovered as (14)CO(2) in the administration of [(14)C]mannitol, while 57% of administered radioactivity was recovered as (14)CO(2) following the administration of [(14)C]glucose for 24 h. The time sequence for the (14)CO(2) excretion from [(14)C]mannitol was delayed as compared to [(14)C]glucose by about 4-6 h (p<0.05). However, when [(14)C]mannitol was orally administered to antibiotics-treated rats, only 3% of administered radioactivity was excreted as (14)CO(2) for 24 h. The total radioactivity of the gastrointestinal contents and feces for 24 h after administration was over 70%, much higher than those of the conventional rats (p<0.05). When a half dose (222 kBq, 52.5 mg) of [(14)C]mannitol was administered to conventional rats, the recovery as (14)CO(2) for 24 h (%) was significantly higher than that of a regular dose of [(14)C]mannitol (105 mg). When cold mannitol (105 mg) was orally administered to the antibiotics-treated rats, about 9% of intact mannitol was excreted in feces within 48 h after administration. However, no intact mannitol was detected in the conventional rats. These results demonstrate that more than 95% of mannitol administered orally is utilized via fermentation by intestinal microbes.


Assuntos
Bactérias/metabolismo , Fermentação , Intestinos/microbiologia , Manitol/metabolismo , Administração Oral , Animais , Antibacterianos , Disponibilidade Biológica , Dióxido de Carbono/análise , Radioisótopos de Carbono/metabolismo , Fezes/química , Mucosa Intestinal/metabolismo , Masculino , Ratos , Ratos Wistar
5.
J Nutr Sci Vitaminol (Tokyo) ; 54(4): 309-14, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18797153

RESUMO

Using a single-group time-series design, we determined that osmotic diarrhea caused by maltitol ingestion was suppressed by the addition of not only soluble but also insoluble dietary fiber in healthy humans. We then clarified that cellulose delayed gastric emptying in rats. Twenty-seven healthy volunteers ingested maltitol step-wise at doses of 15, 20, 25, 30, 35, 40 and 45 g from small to large amounts. Within that range of ingested amounts, 22 out of 27 subjects experienced osmotic diarrhea from maltitol ingestion, and the minimal dose level of maltitol that induced osmotic diarrhea (MMD) was established for each subject. When 5 g of cellulose was added to the MMD, osmotic diarrhea was suppressed in 13 out of 19 subjects (68.4%), while partially hydrolyzed alginate-Na (PHA-Na), a soluble dietary fiber, suppressed osmotic diarrhea in 10 out of 20 subjects (50.0%). When a mixed solution of cellulose and maltitol was administered to rats, the gastric emptying of maltitol was significantly delayed at 30 and 60 min after administration (p=0.019, p=0.013), respectively. PHA-Na also significantly delayed gastric emptying at 30 min (p=0.013). In conclusion, cellulose can suppress the osmotic diarrhea caused by maltitol ingestion in humans and delay the gastric emptying of maltitol in rats. A new physiological property of cellulose was clarified in this study.


Assuntos
Celulose/administração & dosagem , Diarreia/induzido quimicamente , Diarreia/tratamento farmacológico , Diuréticos Osmóticos/administração & dosagem , Maltose/análogos & derivados , Álcoois Açúcares/administração & dosagem , Alginatos/administração & dosagem , Animais , Fibras na Dieta/administração & dosagem , Relação Dose-Resposta a Droga , Interações Medicamentosas , Feminino , Esvaziamento Gástrico/efeitos dos fármacos , Humanos , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/fisiologia , Masculino , Maltose/administração & dosagem , Ratos , Ratos Wistar , Estômago/efeitos dos fármacos , Estômago/fisiologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...